Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway. [PDF]
Front OncolDu S +8 more
europepmc +1 more source
In reply: Why selinexor remains a subpar option? [PDF]
OncologistMohyuddin GR, Meirson T.
europepmc +1 more source
Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. [PDF]
Front OncolLentz RW +15 more
europepmc +1 more source
Comment on "how the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes". [PDF]
OncologistRichter J, Davis M, Chai Y.
europepmc +1 more source
Selinexor as a novel anti-cancer agent
, 2020 Selinexor as a novel anti-cancer agent, clinical trials, results and discussion on them.
openaire +1 more source
Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K/AKT inhibition. [PDF]
Clin EpigeneticsLin J +9 more
europepmc +1 more source
Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting. [PDF]
J Hematol OncolWei R, Yang S.
europepmc +1 more source
A new therapeutic approach to <i>KRAS</i> mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition. [PDF]
Transl Lung Cancer Resvon Itzstein MS, Gerber DE.
europepmc +1 more source
Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis. [PDF]
Ann MedTan S, Li Y, Cao Y, Sun W, Hui W.
europepmc +1 more source